Activation of soluble guanylyl cyclase by YC‐1 in aortic smooth muscle but not in ventricular myocardium from rat
- 1 December 1997
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 122 (7) , 1523-1529
- https://doi.org/10.1038/sj.bjp.0701542
Abstract
The effects of YC‐1 (3‐(5′‐hydroxymethyl‐2′‐furyl)‐1‐benzyl indazole), an activator of soluble guanylyl cyclase, on tension, levels of cyclic GMP and cyclic AMP, and cardiac L‐type Ca2+‐current (ICa(L)) were investigated in aortic smooth muscle and ventricular heart muscle from rat. YC‐1 (0.1–30 μM) induced a concentration‐dependent relaxation in aortic rings precontracted with phenylephrine (3 μM). The relaxant effects of YC‐1 were reversed by 1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one (30 μM; ODQ), potentiated by zaprinast (10 μM) and antagonized by Rp‐8‐Br‐cGMPS (100 μM). In ventricular heart muscle strips, YC‐1 (30 μM) exhibited no effects on force of contraction (Fc) in the absence or presence of either zaprinast (10 μM) or 3‐isobutyl‐1‐methylxanthine (30 μM). Fc was slightly increased by YC‐1 (30 μM) in the presence of isoprenaline (100 nM), but this effect was not influenced by ODQ (30 μM). Cardiac ICa(L) was not significantly affected by YC‐1 (30 μM), either in the absence or presence of isoprenaline (30 nM). In aortic rings, cyclic GMP levels were increased almost 3 fold by YC‐1 (30 μM); this effect was abolished by ODQ (30 μM). In isolated ventricular cardiomyocytes, cyclic GMP levels were not affected by YC‐1 (30 μM) but almost doubled by activation of particular guanylyl cyclase with atriopeptin II (100 nM). YC‐1 (30 μM) did not increase cyclic AMP levels either in aortic rings or in ventricular cardiomyocytes. In contrast, isoprenaline (3 μM) increased cyclic AMP levels about two fold in both tissues. In cardiomyocytes, the effect of isoprenaline (3 μM) was slightly enhanced by YC‐1 (30 μM). It is concluded that relaxation of smooth muscle preparations by YC‐1 is mediated mainly by activation of soluble guanylyl cyclase and subsequent increase in cyclic GMP levels. The failure of YC‐1 to affect cardiac Fc, levels of cyclic GMP, and ICa(L) suggests that soluble guanylyl cyclase is not influenced by YC‐1 in rat heart muscle or only barely present in this tissue.Keywords
This publication has 33 references indexed in Scilit:
- Nitric Oxide and Cardiac FunctionCirculation Research, 1996
- Differential effects of nitric oxide donors on basal and electrically evoked release of acetylcholine from guinea‐pig myenteric neuronesBritish Journal of Pharmacology, 1996
- Inhibition of nitrergic relaxations by a selective inhibitor of the soluble guanylate cyclaseBritish Journal of Pharmacology, 1996
- Low Increase in cGMP Induced by Organic Nitrates and Nitrovasodilators Improves Contractile Response of Rat Ventricular MyocytesCirculation Research, 1996
- The new NO donor SPM3672 increases cGMP and improves contraction in rat cardiomyocytes and isolated heartEuropean Journal of Pharmacology, 1995
- Role of nitric oxide in the regulation of myocardial functionProgress in Cardiovascular Diseases, 1995
- Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscleNature, 1994
- Biosynthesis and Metabolism of Endothelium-Derived Nitric OxideAnnual Review of Pharmacology and Toxicology, 1990
- Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patchesPflügers Archiv - European Journal of Physiology, 1981
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976